Iranian Red Crescent Medical Journal

Published by: Kowsar

Botulinum Toxin Type A Therapy in Migraine: Preclinical and Clinical Trials

Yu-Feng Shao 1 , Yi Zhang 2 , Peng Zhao 1 , 3 , Wen-Jun Yan 2 , Xiang-Pan Kong 1 , Lin-Lan Fan 4 and Yi-Ping Hou 1 , *
Authors Information
1 Department of Neuroscience, Anatomy, Histology and Embryology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
2 Department of Neurology and Pain Treatment, Gansu Provincial People Hospital, Lanzhou, China
3 Gansu University of Traditional Chinese Medicine, Lanzhou, China
4 Medical Experimental Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China
Article information
  • Iranian Red Crescent Medical Journal: October 1, 2013, 15 (10); e7704
  • Published Online: October 5, 2013
  • Article Type: Research Article
  • Received: August 11, 2012
  • Revised: January 5, 2013
  • Accepted: April 8, 2013
  • DOI: 10.5812/ircmj.7704

To Cite: Shao Y, Zhang Y, Zhao P, Yan W, Kong X, et al. Botulinum Toxin Type A Therapy in Migraine: Preclinical and Clinical Trials, Iran Red Crescent Med J. 2013 ; 15(10):e7704. doi: 10.5812/ircmj.7704.

Abstract
Copyright © 2013, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Jensen K. Extracranial blood flow, pain and tenderness in migraine. Clinical and experimental studies. Acta Neurol Scand Suppl. 1993; 147: 1-27[PubMed]
  • 2. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000; 47(5): 614-24[PubMed]
  • 3. Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology. 2004; 63(5): 848-52[PubMed]
  • 4. Olesen J. Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs. Pain. 1991; 46(2): 125-32[PubMed]
  • 5. Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P. Future drugs for migraine. Intern Emerg Med. 2009; 4(5): 367-73[DOI][PubMed]
  • 6. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech. 2001; 53(3): 167-78[DOI][PubMed]
  • 7. May A, Goadsby PJ. Substance P receptor antagonists in the therapy of migraine. Expert Opin Investig Drugs. 2001; 10(4): 673-8[DOI][PubMed]
  • 8. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain. 1995; 60(2): 119-23[PubMed]
  • 9. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003; 43 Suppl 1-24[PubMed]
  • 10. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000; 40(6): 445-50[PubMed]
  • 11. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine--classification, characteristics and treatment. Nat Rev Neurol. 2011; 8(3): 162-71[DOI][PubMed]
  • 12. Behmand RA, Tucker T, Guyuron B. Single-site botulinum toxin type a injection for elimination of migraine trigger points. Headache. 2003; 43(10): 1085-9[PubMed]
  • 13. Ashkenazi A. Botulinum toxin type a for chronic migraine. Curr Neurol Neurosci Rep. 2010; 10(2): 140-6[DOI][PubMed]
  • 14. Farinelli I, Coloprisco G, De Filippis S, Martelletti P. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain. 2006; 7(6): 407-12[DOI][PubMed]
  • 15. Aoki KR, Childers MK. Pharmacology in Pain Relief. In The Use of Botulinum Toxin Type A in Pain Management A Clinician's Guide. 2002; : 23-26
  • 16. Poungvarin N. The first world report of botulinum A toxin injection for status migrainosus. J Med Assoc Thai. 2001; 84(8): 1199-203[PubMed]
  • 17. Tamura BM, Chang B. Botulinum toxin: application into acupuncture points for migraine. Dermatol Surg. 2003; 29(7): 749-54[PubMed]
  • 18. Organization WH. Review and analysis of repotrs on controlled clinical trials. 2002;
  • 19. Witt CM, Reinhold T, Jena S, Brinkhaus B, Willich SN. Cost-effectiveness of acupuncture treatment in patients with headache. Cephalalgia. 2008; 28(4): 334-45[DOI][PubMed]
  • 20. Karst M, Rollnik JD, Fink M, Reinhard M, Piepenbrock S. Pressure pain threshold and needle acupuncture in chronic tension-type headache--a double-blind placebo-controlled study. Pain. 2000; 88(2): 199-203[PubMed]
  • 21. Strudwick MW, Hinks RC, Choy ST. Point injection as an alternative acupuncture technique--an exploratory study of responses in healthy subjects. Acupunct Med. 2007; 25(4): 166-74[PubMed]
  • 22. Wang S, Wang W, Li L. Treating neurotic headache by point-injection with Novocain. J Tradit Chin Med. 1990; 10(3): 189-91[PubMed]
  • 23. Ga H, Choi JH, Park CH, Yoon HJ. Acupuncture needling versus lidocaine injection of trigger points in myofascial pain syndrome in elderly patients--a randomised trial. Acupunct Med. 2007; 25(4): 130-6[PubMed]
  • 24. Wong YK, Cheng J. A case series of temporomandibular disorders treated with acupuncture, occlusal splint and point injection therapy. Acupunct Med. 2003; 21(4): 138-49[PubMed]
  • 25. Yeom MJ, Lee HC, Kim GH, Shim I, Lee HJ, Hahm DH. Therapeutic effects of Hominis placenta injection into an acupuncture point on the inflammatory responses in subchondral bone region of adjuvant-induced polyarthritic rat. Biol Pharm Bull. 2003; 26(10): 1472-7[PubMed]
  • 26. Vamos E, Pardutz A, Fejes A, Tajti J, Toldi J, Vecsei L. Modulatory effects of probenecid on the nitroglycerin-induced changes in the rat caudal trigeminal nucleus. Eur J Pharmacol. 2009; 621(1-3): 33-7[DOI][PubMed]
  • 27. Wen WD, Yuan F, Wang JL, Hou YP. Botulinum toxin therapy in the ovalbumin-sensitized rat. Neuroimmunomodulation. 2007; 14(2): 78-83[DOI][PubMed]
  • 28. Hou YP, Zhang YP, Song YF, Zhu CM, Wang YC, Xie GL. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can J Physiol Pharmacol. 2007; 85(2): 209-14[DOI][PubMed]
  • 29. Headache Classification Subcommittee of the International Headache Society. 2004; : 44-48
  • 30. Sostak P, Krause P, Forderreuther S, Reinisch V, Straube A. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain. 2007; 8(4): 236-41[DOI][PubMed]
  • 31. Mathew NT, Kailasam J, Meadors L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache. 2008; 48(2): 194-200[DOI][PubMed]
  • 32. Lui Y, Wang J. Illustration of composed acupoint in acupuncture-moxibustion use. 2008; : 1-312
  • 33. Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res. 1995; 682(1-2): 167-81[PubMed]
  • 34. Tvedskov JF, Iversen HK, Olesen J. A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalalgia. 2004; 24(10): 875-82[DOI][PubMed]
  • 35. Tvedskov JF, Thomsen LL, Iversen HK, Williams P, Gibson A, Jenkins K, et al. The effect of propranolol on glyceryltrinitrate-induced headache and arterial response. Cephalalgia. 2004; 24(12): 1076-87[DOI][PubMed]
  • 36. Tassorelli C, Blandini F, Greco R, Nappi G. Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. J Chem Neuroanat. 2004; 27(1): 23-32[DOI][PubMed]
  • 37. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007; 120: 2864-74[DOI][PubMed]
  • 38. Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008; 101(3): 366-70[DOI][PubMed]
  • 39. Wang L, Cardini F, Zhao W, Regalia AL, Wade C, Forcella E, et al. Vitamin K acupuncture pint injection for severe primary dysmenorrhea: an international pilot study. MedGenMed. 2004; 6(4): 45[PubMed]
  • 40. Lou L, Chen WJ. Development of acu-injedtion treatment. J Clin Acupunct Moxibust. 2001; 17: 55-56
  • 41. de Vernejoul P, Albarede P, Darras JC. Nuclear medicine and acupuncture message transmission. J Nucl Med. 1992; 33(3): 409-12[PubMed]
  • 42. Gobel H. Botulinum toxin in migraine prophylaxis. J Neurol. 2004; 251 Suppl 1-11[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments